Patients
malignancy, tumor, CRS
ONCOLOGY, TUMOR
Eligible patients had histological evidence of a metastatic low-grade (defined as well- or well-to-moderate–differentiated) mucinous AA, with radiographic images demonstrating the presence of PMP, and were not considered candidates for complete CRS. Surgical candidacy was determined by consultation with peritoneal surface malignancy surgeons at MDACC, in coordination with our multidisciplinary peritoneal surface malignancy conference. Criteria for determining nonresectability were: medical comorbidities presenting high surgical risk; tumor bulk and location, such as encasement of the liver hilum or extensive small bowel involvement that would preclude the possibility of obtaining a complete cytoreduction (completeness of cytoreduction score of 0 or 1); or prior CRS that was unsuccessful. Patients were required to have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2, be aged at least 18 years, and have adequate bone marrow function (hemoglobin, ≥9.0 g/dL [to convert to grams per liter, multiply by 10]; platelets, ≥75 cells × 10